{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:19:41Z","timestamp":1787789981821,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2025-25454860"],"award-info":[{"award-number":["RS-2025-25454860"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52212-4","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:45:46Z","timestamp":1781297146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study"],"prefix":"10.1038","volume":"16","author":[{"given":"Jae Ryong","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehwi","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Chul","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Seungkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Retina Biosimilar Study Group (Inter BIOS Group)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Vazquez-Alfageme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikulaa","family":"Parachuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alay","family":"Banker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourous A.","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeng\u00fcl","family":"\u00d6zdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodjikian","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Bilgic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Holekemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Tufail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Yannuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitaranjan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debdulal","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian W. M.","family":"Wintergerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Parolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil Ghasemi","family":"Falavarjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearse A.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Zinkernagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ueda-Consolvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"52212_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","volume":"96","author":"MW Stewart","year":"2012","unstructured":"Stewart, M. W. Aflibercept (VEGF Trap-eye): The newest anti-VEGF drug. Br. J. Ophthalmol. 96, 1157\u20131158 (2012).","journal-title":"Br. J. Ophthalmol."},{"key":"52212_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal Aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119, 2537\u20132548 (2012).","journal-title":"Ophthalmology"},{"key":"52212_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrd3700","volume":"11","author":"MW Stewart","year":"2012","unstructured":"Stewart, M. W., Grippon, S. & Kirkpatrick, P. Aflibercept. Nat. Rev. Drug Discov. 11, 269\u2013270 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"52212_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40123-021-00354-1","volume":"10","author":"R Anguita","year":"2021","unstructured":"Anguita, R. et al. A review of Aflibercept treatment for macular disease. Ophthalmol. Ther. 10, 413\u2013428 (2021).","journal-title":"Ophthalmol. Ther."},{"key":"52212_CR5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","volume":"11","author":"SM Hariprasad","year":"2022","unstructured":"Hariprasad, S. M. et al. An introduction to biosimilars for the treatment of retinal diseases: A narrative review. Ophthalmol. Ther. 11, 959\u2013982 (2022).","journal-title":"Ophthalmol. Ther."},{"key":"52212_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ajo.2020.11.017","volume":"224","author":"A Sharma","year":"2021","unstructured":"Sharma, A. et al. Biosimilars for retinal diseases: An update. Am. J. Ophthalmol. 224, 36\u201342 (2021).","journal-title":"Am. J. Ophthalmol."},{"key":"52212_CR7","doi-asserted-by":"publisher","unstructured":"Lee, H., Sharma, A. & Woo, S. J. Clinical trials of aflibercept biosimilars: A review. J. Ocul. Pharmacol. Ther. https:\/\/doi.org\/10.1089\/jop.2025.0040 (2025).","DOI":"10.1089\/jop.2025.0040"},{"key":"52212_CR8","unstructured":"Research, C. for D. E. and. FDA Approves First Interchangeable Biosimilars to Eylea to Treat Macular Degeneration and Other Eye Conditions (FDA, 2024). https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye"},{"key":"52212_CR9","unstructured":"Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761350."},{"key":"52212_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","volume":"141","author":"SJ Woo","year":"2023","unstructured":"Woo, S. J. et al. Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: A phase 3 randomized clinical trial. JAMA Ophthalmol. 141, 668\u2013676 (2023).","journal-title":"JAMA Ophthalmol."},{"key":"52212_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001561","author":"SR Sadda","year":"2023","unstructured":"Sadda, S. R. et al. Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial. BMJ Open Ophthalmol. https:\/\/doi.org\/10.1136\/bmjophth-2023-001561 (2023).","journal-title":"BMJ Open Ophthalmol."},{"key":"52212_CR12","doi-asserted-by":"publisher","unstructured":"Rashid, M. et al. Efficacy and safety of aflibercept biosimilars compared to reference aflibercept for retinal diseases: A systematic review and meta-analysis. Surv. Ophthalmol. S0039625725002139 (2025) https:\/\/doi.org\/10.1016\/j.survophthal.2025.11.007.","DOI":"10.1016\/j.survophthal.2025.11.007"},{"key":"52212_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","volume":"107","author":"NM Bressler","year":"2023","unstructured":"Bressler, N. M. et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br. J. Ophthalmol. 107, 384\u2013391 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"52212_CR14","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1038\/s41433-025-04030-7","volume":"39","author":"A Sharma","year":"2025","unstructured":"Sharma, A. et al. FYB-201 biosimilar ranibizumab (Ongavia\/Ranivisio\/Cimerli) efficacy and safety in clinical settings\u2014FORCE study. Eye 39, 3129\u20133134 (2025).","journal-title":"Eye"},{"key":"52212_CR15","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1038\/s41598-025-34325-4","volume":"16","author":"JR Song","year":"2026","unstructured":"Song, J. R. et al. Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience\u2014ROSE Korea Study. Sci. Rep. 16, 4220 (2026).","journal-title":"Sci. Rep."},{"key":"52212_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251322213","author":"A Sharma","year":"2025","unstructured":"Sharma, A. et al. Biosimilar Ranibizumab (Ranieyes) safety and efficacy in the real world: BRESER Study. J. Vitreoretin. Dis. https:\/\/doi.org\/10.1177\/24741264251322213 (2025).","journal-title":"J. Vitreoretin. Dis."},{"key":"52212_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","volume":"142","author":"SB Bressler","year":"2024","unstructured":"Bressler, S. B. et al. Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial. JAMA Ophthalmol. 142, 952\u2013960 (2024).","journal-title":"JAMA Ophthalmol."},{"key":"52212_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.21561\/jor.2021.6.2.99","volume":"6","author":"Y-J Choi","year":"2021","unstructured":"Choi, Y.-J., Choi, Y. J., Cho, Y. W., Yoo, W.-S. & Chung, I. Y. Clinical outcomes of aflibercept treatment for treatment-naive exudative age-related macular degeneration. J. Retina 6, 99\u2013109 (2021).","journal-title":"J. Retina"},{"key":"52212_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3341\/kjo.2024.0083","volume":"38","author":"JY Moon","year":"2024","unstructured":"Moon, J. Y., Kim, H. J. & Cho, S. C. Two-year outcomes of intravitreal Aflibercept injection for neovascular age-related macular degeneration with \u201cObserve before Treat-and-Extend\u201d method. Korean J. Ophthalmol. 38, 380\u2013391 (2024).","journal-title":"Korean J. Ophthalmol."},{"key":"52212_CR20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1038\/s41433-025-03813-2","volume":"39","author":"S Avadzadeh","year":"2025","unstructured":"Avadzadeh, S., Sharma, A., Parvaresh, M. M. & Ghasemi Falavarjani, K. Aflibercept 2 mg biosimilar (Tyalia)\u2014real-world experience from Iran (ATRIA study). Eye 39, 2159\u20132163 (2025).","journal-title":"Eye"},{"key":"52212_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.survophthal.2024.03.009","volume":"69","author":"NM Bressler","year":"2024","unstructured":"Bressler, N. M. et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review. Surv. Ophthalmol. 69, 521\u2013538 (2024).","journal-title":"Surv. Ophthalmol."},{"key":"52212_CR22","first-page":"1044","volume":"6","author":"P-H Gabrielle","year":"2022","unstructured":"Gabrielle, P.-H. et al. Incidence, risk factors, and outcomes of rhegmatogenous retinal detachment after intravitreal injections of anti-VEGF for retinal diseases: Data from the fight retinal blindness!. Registry. Ophthalmol. Retina 6, 1044\u20131053 (2022).","journal-title":"Registry. Ophthalmol. Retina"},{"key":"52212_CR23","unstructured":"Editor, B. Samsung Bioepis\u2019 Biosimilar Aflibercept Set for Korean Market after Appeal Win. Pearce IP https:\/\/www.pearceip.law\/2025\/12\/05\/samsung-bioepis-biosimilar-aflibercept-set-for-korean-market-after-appeal-win\/ (2025)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52212-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:46:16Z","timestamp":1787787976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52212-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52212"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52212-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Se Joon Woo received consulting fees from Abbott, Alteogen, Astellas, Curacle, Janssen, Novelty Nobility, Pharmabcine, Optus, Santen, Samsung Bioepis, Samil, Scai Therapeutics, Sometech, lecture fees from Abbvie, Alcon, Bayer, Chong Kun Dang, Kukje, Novartis, Roche, Sam Chun Dang, Santen, Samil, Zeiss; grants from Alcon, Alteogen, Bayer, Curacle, Janssen, Kyowa Kirin, Novelty Nobility, Novartis, Pharmabcine, Roche, Samsung Bioepis, Taejoon, Zeiss; owns equity of RetiMark and Panolos Bioscience. Min Sagong reports being a consultant for and receiving grant support and a lecture fee from Samsung Bioepis, Novartis, Bayer, Roche, Allergan\/Abbvie, Celltrion, Alteogen, Alcon, Johnson & Johnson, Sam Chun Dang, PharmAbcine, and Curacle, and receiving grant support from Janssen, Kyowa Kirin, and 4D Molecular Therapeutics. Ashish Sharma: Consultant for Oculis, Novartis, Allergan, Bayer, Lupin, Intas, Ajanta and Sun Pharma Speaker fee MS Pharma, Abdi \u0130brahim \u0130la\u00e7 San. ve Tic, Samil Pharma, Roche Other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"During the preparation of this work the author(s) used ChatGPT (OpenAI) to improve language clarity and polish expressions. After using this tool\/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"26909"}}